It has also been approved in the EU, UK, and Canada. AstraZeneca-partnered Beyfortus (nirsevimab) is the first RSV prevention medicine that can be used in all infants and has greater efficacy than ...
AstraZeneca boasts a remarkably healthy drug portfolio and a pipeline of promising drugs in clinical development. Read why ...
AstraZeneca and Sanofi’s long-acting antibody Beyfortus has been approved in China for the prevention of respiratory syncytial virus (RSV) infections in newborns and infants, opening up a major ...
Hosted on MSN21d
AstraZeneca Rises Almost 9% in a Month: How to Play the StockAstraZeneca AZN stock has risen 8.6% in the ... commonly referred to as ATTRv-PN and respiratory syncytial virus antibody Beyfortus (in partnership with Sanofi [SNY]). Key pipeline candidates ...
AstraZeneca records 50% share of gross profits on sales of Beyfortus in major markets outside the United States received from Sanofi as Alliance revenues. It also records Beyfortus product sales ...
AstraZeneca PLC beat Q4 and full-year 2024 ... the others being cancer meds Truqap (breast), and Imjudo (liver), RSV vaccine Beyfortus, Wainua (polyneuropathy), Airsupra (asthma), and Voydeya ...
AstraZeneca’s AZN fourth-quarter 2024 core earnings of $1.05 per American depositary share (“ADS”) missed the Zacks Consensus Estimate of $1.07. Core earnings of $2.09 per share rose 44% ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback